NxStage Medical Launches NxStage Plus One at 2014 Annual Dialysis Conference
Leading home dialysis company announces new patient outreach campaign aimed at increasing awareness of home hemodialysis among ESRD patients
ATLANTA, Feb. 6, 2014 /PRNewswire/ — NxStage Medical Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced from the Annual Dialysis Conference (ADC) in Atlanta, Georgia (booth #411) the introduction of a new patient outreach campaign, NxStage Plus One. This campaign aims to increase awareness of home hemodialysis with the NxStage® System One(TM) through a series of activities and events focused on encouraging NxStage patients to share their experiences with other end stage renal disease (ESRD) patients. The campaign is designed to bring existing and potential ESRD patients together based on the premise that one-to-one communication is the most compelling way to learn about the benefits of home hemodialysis and support one another in coping with their chronic disease.
NxStage Plus One aims to empower thousands of the Company’s patients to share their stories with at least one other ESRD patient in the hopes of increasing awareness for home hemodialysis and access to the life-changing benefits possible with this therapy. According to a recent study on patient dialysis experience by Anna E. Winterbottom from the Leeds Institute for Health Sciences, “information presented in the first person (e.g. the patient’s account) was more than twice as likely to influence other people’s choices than information presented in the third person (e.g. the doctor talking about the patient’s experience).” NxStage Plus One aims to deliver emotionally-charged success stories from home hemodialyzor to potential home hemodialyzor, and increase access to and knowledge of home hemodialysis treatment availability.
“Over the years we have consistently been impressed by the incredible success of patient-to-patient communication and how it continually advocates for and improves access to home hemodialysis therapy,” said Joseph E. Turk, Jr., president of NxStage Medical, Inc. “With NxStage Plus One we will facilitate these discussions to help patients choose the best treatment option for their health and lifestyle requirements.”
At ADC on Sunday, February 9, 2014 NxStage will hold its first educational program and regional support group meeting bringing together existing and potential patients in Atlanta to explore the opportunities and benefits a lifestyle with home hemodialysis has to offer. The nationwide rollout of the complete NxStage Plus One program will take place during National Kidney Month in March 2014.
Consistent with the spirit of NxStage Plus One, NxStage will provide medical professionals visiting its booth the opportunity to learn about home hemodialysis therapy with the NxStage System One via direct interaction with a patient dialyzing live. The experience affords nurses and healthcare providers the ability to see a patient perform therapy with the NxStage System One and hear the patient’s firsthand account of her therapy experience.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs – at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at www.nxstage.com.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE NxStage Medical, Inc.